Gene Therapy Market Size, Share & Trend Report

Gene Therapy Market Size, Share & Trend Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-2-68038-179-5
Number of Pages: 162
Format: Electronic (PDF)

Historical Range: 2018 - 2022
Industry: Healthcare

Market Segmentation

Gene Therapy Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-Cell Lymphoma
- ADA-SCID
- Melanoma (lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral Arterial Disease
- Spinal Muscular Atrophy (SMA)
- Others
Gene Therapy Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)
- Intravenous
- Others
Gene Therapy Vector Type Outlook (Revenue, USD Million; 2018 - 2030)
- Lentivirus
- AAV
- RetroVirus & gamma RetroVirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-viral Plasmid Vector
- Others
Gene Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
    - Acute Lymphoblastic Leukemia (ALL)
    - Inherited Retinal Disease
    - Large B-Cell Lymphoma
    - ADA-SCID
    - Melanoma (lesions)
    - Beta-Thalassemia Major/SCD
    - Head & Neck Squamous Cell Carcinoma
    - Peripheral Arterial Disease
    - Spinal Muscular Atrophy (SMA)
    - Others
  - North America Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
    - Lentivirus
    - AAV
    - RetroVirus & gamma RetroVirus
    - Modified Herpes Simplex Virus
    - Adenovirus
    - Non-viral Plasmid Vector
    - Others
  - North America Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Others
  - U.S.
    - U.S. Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - U.S. Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - U.S. Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - Canada
    - Canada Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - Canada Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - Canada Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
- Europe
  - Europe Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
    - Acute Lymphoblastic Leukemia (ALL)
    - Inherited Retinal Disease
    - Large B-Cell Lymphoma
    - ADA-SCID
    - Melanoma (lesions)
    - Beta-Thalassemia Major/SCD
    - Head & Neck Squamous Cell Carcinoma
    - Peripheral Arterial Disease
    - Spinal Muscular Atrophy (SMA)
    - Others
  - Europe Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
    - Lentivirus
    - AAV
    - RetroVirus & gamma RetroVirus
    - Modified Herpes Simplex Virus
    - Adenovirus
    - Non-viral Plasmid Vector
    - Others
  - Europe Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Others
  - Germany
    - Germany Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - Germany Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - Germany Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - UK
    - UK Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - UK Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - UK Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - France
    - France Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - France Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
  - Italy
    - Italy Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - Italy Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - Italy Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - Spain
    - Spain Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - Spain Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - Spain Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
- Asia Pacific
  - Asia Pacific Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
    - Acute Lymphoblastic Leukemia (ALL)
    - Inherited Retinal Disease
    - Large B-Cell Lymphoma
    - ADA-SCID
    - Melanoma (lesions)
    - Beta-Thalassemia Major/SCD
    - Head & Neck Squamous Cell Carcinoma
    - Peripheral Arterial Disease
    - Spinal Muscular Atrophy (SMA)
    - Others
  - Asia Pacific Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
    - Lentivirus
    - AAV
    - RetroVirus & gamma RetroVirus
    - Modified Herpes Simplex Virus
    - Adenovirus
    - Non-viral Plasmid Vector
    - Others
  - Asia Pacific Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Others
  - China
    - China Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - China Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - China Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - Japan
    - Japan Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - Japan Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - Japan Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - Australia
    - Australia Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - Australia Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - Australia Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others
  - South Korea
    - South Korea Gene Therapy market indication outlook (Revenue, USD Million, 2018 - 2030)
      - Acute Lymphoblastic Leukemia (ALL)
      - Inherited Retinal Disease
      - Large B-Cell Lymphoma
      - ADA-SCID
      - Melanoma (lesions)
      - Beta-Thalassemia Major/SCD
      - Head & Neck Squamous Cell Carcinoma
      - Peripheral Arterial Disease
      - Spinal Muscular Atrophy (SMA)
      - Others
    - South Korea Gene Therapy market vector type outlook (Revenue, USD Million, 2018 - 2030)
      - Lentivirus
      - AAV
      - RetroVirus & gamma RetroVirus
      - Modified Herpes Simplex Virus
      - Adenovirus
      - Non-viral Plasmid Vector
      - Others
    - South Korea Gene Therapy market route of administration outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Others

Gene Therapy Market Dynamics

Driver: Robust gene therapy pipeline

Researchers are working to make gene therapy available at clinics. Although very few patients have so far received effective gene therapy treatments, gene therapy holds high potential in revolutionizing disease treatment regimens by targeting the genes responsible for disease pathogenesis. Various universities and institutes are observed to exhibit a broad portfolio of gene therapy in the pipeline, which, in turn, is expected to boost revenue generation in the near future. Clinical trials for gene therapy increased significantly from 2017 to 2018, after the FDA approved the first gene therapy. This first approval propelled the confidence of entities in the gene therapy field. Hence, robust pipeline is expected to fuel the growth of this market.

Driver: Introduction of technological advancements

Gene therapy involves the introduction of a gene of interest through recombinant DNA technology into the host’s genome to repair the mutations that underlie the disease. Few drawbacks with gene therapy pose challenges in delivering recombinant DNA into host cells. Continuous advancements in recombinant DNA technology are expected to enhance the efficiency of gene therapy in the coming years. Hence, the ongoing advancements in recombinant DNA technology are expected to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in context of various gene-editing tools and expression systems to augment the R&D for gene therapy products.

Restraint: Absence of effective diagnosis framework

Controversies and debates over the ethics of using gene technology in human disease treatment have been increasing with the introduction of various gene-editing tools. As gene therapy involves alterations in genes, it has raised many ethical concerns. Because of these ethical issues surrounding gene therapy, the U.S. government prohibited the use of federal funds for research on germline gene therapy in people. Gene therapy allows humans to save future generations in a family from particular genetic disorders. However, it is anticipated to affect fetus development in unexpected ways. Furthermore, regulatory agencies such as the FDA have established several guidance documents demonstrating the preclinical and clinical activities as a key to regulate and review gene therapy products. The presence of stringent regulatory guidelines pertaining to the approval of gene therapy products has slowed down the growth of this market.

What Does This Report Include?

This section will provide insights into the contents included in this smart gene therapy report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Gene therapy market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Gene therapy market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.